{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T21:17:24Z","timestamp":1785532644777,"version":"3.56.0"},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In the phase II KRYSTAL-1 trial, the KRASG12C inhibitor adagrasib yielded an overall response rate of 43% and a disease control rate of 80% in patients with previously treated KRASG12C-mutant non\u2013small cell lung cancer. After a median follow up of 12.9 months, overall survival was 11.7 months. The drug also shrank brain metastases in 33% of patients who had them.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nb2022-0042","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T15:54:39Z","timestamp":1654530879000},"page":"OF1-OF1","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adagrasib Response Remains Strong in NSCLC"],"prefix":"10.1158","volume":"12","member":"1086","published-online":{"date-parts":[[2022,6,6]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/doi\/10.1158\/2159-8290.CD-NB2022-0042\/699383\/Adagrasib-Response-Remains-Strong-in","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/12\/8\/OF1\/707248\/Adagrasib-Response-Remains-Strong-in","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/12\/8\/OF1\/707248\/Adagrasib-Response-Remains-Strong-in","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T15:03:31Z","timestamp":1659971011000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/12\/8\/OF1\/707248\/Adagrasib-Response-Remains-Strong-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":0,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,6,6]]},"published-print":{"date-parts":[[2022,8,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2022-0042","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]}}}